5/22/24 - vrockstar - NYSE:MDT - valuation interesting at 17x PE for what looks like a nice cash generator (6% fcf yield minimally). the issue is really growth which is either flat at best this yr or probably -ve. these unfortunatley are simply un-ownable companies in this tape which is prioritizing growth-ONLY. so while i'd be interested lower and am setting a...
NYSE:MDT broke out from the channel and is consolidating in a flag. It looks primed for the next leg up. 🚀
Price targets:
$92
$96
$100
$104
Downside risk:
$76
In the medical device and pharmaceutical sectors, contrasting financial metrics and market dynamics between Medtronic plc (MDT) and Bristol-Myers Squibb Company (BMY) present a compelling scenario for investors. Based on their respective financial performances and market positions, it could be strategic to consider buying BMY while contemplating selling MDT.
...
If you haven`t bought the previous dip in MDT:
Then analyzing the options chain and the chart patterns of MDT Medtronic plc prior to the earnings report this week,
I would consider purchasing the 75usd strike price at the money Calls with
an expiration date of 2023-11-24,
for a premium of approximately $1.24.
If these options prove to be profitable prior to the...
MDT has increased its dividend for 46 consecutive years. Easing supply-chain issues, new product launches, and higher demand for medical procedures have been supporting Medtronic’s performance.
In addition, the company is focusing on digital technology adoption and cost-saving measures, with a target of achieving $1 billion in savings by 2025.
NYSE:MDT Ouch! A false break out and a fast breakdown. Lets see if 200DMA can provide some support. Otherwise, a trip down to $76 is possible. ER is on 22nd August. Its a make it or break it quarter. 👀
copy & paste directly from Argus,
Medtronic is one of the world's largest medical technology and solutions companies. The company’s devices focus on cardiac rhythm management, spinal and surgical navigation technologies, treatments
for diabetes and neurological conditions, vascular therapies, and cardiac surgery. MDT has been a poor performer versus the S&P 500...
NYSE:MDT Breaking out of the descending wedge with a ☕️.
If the stock can break above $92, it can run to $105. Breaking below $84 would be bearish. $89 - 92 is going to be a hard resistance to overcome.
Targets - $92, $100, $105
Downside risk - $76
The PEAD projected a bullish outlook for NYSE:MDT after a negative over reaction following its earnings release placing the stock in drift D with an expected accuracy of 40%.
yep ... Medtronic has been taking advantage of A.I. for years.
"By harnessing the power of AI, data analytics, and sensors, Medtronic's healthcare technologies are helping clinicians create individualized treatment plans to achieve better outcomes for more people in more places. From the world’s first hybrid closed-loop insulin delivery system to robotic-assisted...
MDT beat analysts' estimates but guided somewhat dovish. The market has penalized the stock - it could be an overreaction. The management executes well on the business. I expect higher prices.
When price clears 92.39
With daily volume greater than 6.875M
Target: 109.00 area
Depending on your risk tolerance: 86.68 gets you 3/1 Risk/Reward, however I recommend your stop be a bit tighter, maybe slightly under the low (89.43) on March 2nd.
Caution: Earnings on May 25th, Resistance @ 95.60
This trade idea is not trade advice. This idea is strictly based on...
The PEAD projected a bearish outlook for $MDT after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 80%.
NYSE:MDT has not been making any lower low (closing price) in the weekly chart since W4 November 2022.
Last 4h candle is breaking out the downtrend line (peak line on 21- Apr-2022)
If the price can breakout $ 81.24 - 81.64 barrier, first target will be the flat target at $87.44
In the bigger picture, price around $95 will be the target for the upside...
I am doing a small account challenge and ran across this chart on finviz. I am not sure if this will be the one I choose to take but I like the odds here.
RSI divergence
GAP down to Demand Zone (2020-3-23)
Wedge bottom touch
Might be exhaustion GAP
Earning 11/22/2022 Est. 1.3
Entry 77
Stop 72
Target 86, 95
Risk management is much more important than a good entry point.
I am not a PRO trader.
In my trading plan, the Max Risk of each short term trade should be less than 1% of an account.
